TNFSF13B and hematologic disorder: Currently, there are several drugs used to target B-cell survival in humans, mainly in hematological malignancies: belimumab, a BAFF mAb, blisibimod, a selective antagonist of BAFF,29 ianalumab, a mAb to BAFF-R,30 and atacicept, a TACI recombinant fusion protein that binds both BAFF and APRIL31 (Figure 2).